Results

1–10 of 113 results for Aflibercept

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Eric Nudleman, MD, PhD
Annual Meeting Talks
2023
Six Monthly Intravitreal Aflibercept to Improve Macular Perfusion in Diabetic Retinopathy Without Macular Edema
Yoon Jeon Kim, MD
Annual Meeting Talks
2023
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
Hani Salehi-Had, MD, FASRS
Annual Meeting Talks
2023
Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Glenn J. Jaffe, MD
Annual Meeting Talks
2023
Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023
Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023